Computational Modelling and Simulation of Carbon Nanotubes

Author(s):  
K.M. Liew ◽  
Y.Z. Sun
2021 ◽  
Author(s):  
Obaidur Rahman Mohammed ◽  
D V Suresh Koppisetty ◽  
Hamid M Lankarani

Author(s):  
Graham Coates ◽  
Meshal Alharbi ◽  
Chunhui Li ◽  
Sangaralingam Ahilan ◽  
Nigel Wright

The resilience of small and medium-sized enterprises (SMEs) to disruptive events is significant as this highly prevalent category of business forms the economic backbone in developed countries. This article provides an overview of the application of a computational modelling and simulation approach to evaluate SMEs' operational resilience to flooding based on combinations of structural and procedural mitigation measures that may be implemented to improve their premises' resistance to flooding and safeguard their business continuity. The approach integrates flood modelling and simulation with agent-based modelling and simulation (ABMS) within a modelled geographical environment. SMEs are modelled as agents based on findings of semi-structured interviews with SMEs that have experienced flooding or are at risk of flooding. In this paper, the ABMS has been applied to a new case study of the major flood event of 2007 in Tewkesbury. Furthermore, to enable an evaluation of the operational resilience of manufacturing SMEs in terms of the relative effectiveness of flood mitigation measures, a new coefficient based on production loss is introduced. Results indicate structural mitigation measures are more effective than procedural measures. While this result is intuitive, the approach provides a means of evaluating the relative effectiveness of combinations of mitigation measures that SMEs may implement to enhance their operational resilience to flooding. This article is part of the theme issue ‘Urban flood resilience’.


Author(s):  
Muhammad Jibran Shahzad Zuberi ◽  
Volkan Esat

Carbon nanotubes (CNTs) are considered to be one of the contemporary materials exhibiting superior mechanical, thermal and electrical properties. A new generation state-of-the-art composite material, carbon nanotube reinforced polymer (CNTRP), utilizes carbon nanotubes as the reinforcing fibre element. CNTRPs are highly promising composite materials possessing the potential to be used in various areas such as automotive, aerospace, defence, and energy sectors. The CNTRP composite owes its frontline mechanical material properties mainly to the improvement provided by the CNT filler. There are challenging issues regarding CNTRPs such as determination of material properties, and effect of chirality and size on the mechanical material properties of carbon nanotube fibres, which warrant development of computational models. Along with the difficulties associated with experimentation on CNTs, there is paucity in the literature on the effects of chirality and size on the mechanical properties of CNTs. Insight into the aforementioned issues may be brought through computational modelling time- and cost-effectively when compared to experimentation. This study aims to investigate the effect of chirality and size of single-walled carbon nanotubes (SWNTs) on its mechanical material properties so that their contribution to the mechanical properties of CNTRP composite may be understood more clearly. Nonlinear finite element models based on molecular mechanics using various element types substituting C-C bond are generated to develop zigzag, armchair and chiral SWNTs over a range of diameters. The predictions collected from simulations are compared to the experimental and computational studies available in the literature.


Author(s):  
Jobin Jose ◽  
Shifali S. ◽  
Bijo Mathew ◽  
Della Grace Thomas Parambi

Abstract: The modern pharmaceutical industry is creating a transition from traditional methods to advanced technologies like artificial intelligence. In the current scenario, continuous efforts are being made to incorporate computational modelling and simulation in drug discovery, development, design, and optimization. With the advancement in technology and modernization, many pharmaceutical companies are approaching in silico trials to develop safe and efficacious medicinal products. To obtain marketing authorization for a medicinal product from the concerned National regulatory Authority, manufacturers must provide evidence for the safety, efficacy, and quality of medical products in the form of in vitro or in vivo methods. However, more recently this evidence was provided to regulatory agencies in the form of modelling and simulation, i.e., in silico evidence. Such evidence (computational or experimental) will only be accepted by the regulatory authorities if it considered as qualified by them and this will require the assessment of the overall credibility of the method. One must consider the scrutiny provided by the regulatory authority to develop or use the new in silico evidence. The United States Food and Drug Administration and European Medicines Agency are the two regulatory agencies in the world that accept and encourage the use of modelling and simulation within the regulatory process. More efforts must be made by other regulatory agencies worldwide to incorporate such new evidence, i.e., modelling and simulation (in silico) within the regulatory process. This review article focuses on the approaches of in silico trials, its verification, validation, and uncertainty quantification involved in the regulatory evaluation of biomedical products that utilize predictive models.


Sign in / Sign up

Export Citation Format

Share Document